Drug intelligence / Profile preview

Vitoss BA

Development stage: Unknown
Lead developer: Stryker
Administration: Implant

Overview

Vitoss BA is a bioactive synthetic bone graft substitute medical device used as a non-structural bone void filler. Originally developed by Orthovita and currently marketed by Stryker, it is composed of a highly porous (up to 90%) beta-tricalcium phosphate (beta-TCP) scaffold, Type I bovine collagen, and bioactive glass. The bioactive glass component releases silicon, sodium, and calcium ions, which are intended to facilitate the bone regeneration process. The device is indicated for use in the extremities, pelvis, and posterolateral spine to treat surgically created or traumatic osseous defects. It is designed to be resorbed and replaced by natural bone during the body's remodeling process.

Brand names: Vitoss BA
Other names: Vitoss BioactiveVitoss BA Bioactive Bone Graft Substitute

Beyond the preview

Go deeper on Vitoss BA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitoss BA.

Explore the full profile